Company: NIVFW
Filing Date: 2025-10-10
Form Type: F-1/A
Source: 0001213900-25-098135
Chunk: 118

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-10
Form: F-1/A
Chunk 118
---
2023 to US$2,987,389 in 2024, primarily attributable to (i) professional fees of US$769,820 incurred in 2024 being related to business combination with ACSA and the convertible note financing; (ii) license fee of US$123,000 in 2024 related to the use of MicroSort technology; and (iii) staff and director salary and personnel cost of US$888,861 in 2024 due to enlargement of sales force and administrative staff to implement our business expansion pan. 71 Other income NewGenIvf’s other income increased from a net other expense of $100,095 to a net income of $3,938,408 from the six months period ended June 30, 2024 to the six months period ended June 30, 2025. NewGenIvf’s other income increased from US$111,837 in 2023 to US$971,391 in 2024, primarily attributable to a partial waiver of promissory note and legal fee payable. Interest expense NewGenIvf’s interest expense increased by approximately 0.04%, from US$120,162 in the six months period ended June 30, 2024 to US$125,489 in the six months period ended June 30, 2025. NewGenIvf’s interest expense increased from US$46,179 in 2023 to US$778,656 in 2024 as a result of more interest expenses on convertible note issuance in 2024. Tax income (expense) NewGenIvf made no provision for income taxes in 2024 and 2023. Thailand’s taxable income in 2024, if any, would be offset by the tax loss carryforward from previous years. With the disposition of First Fertility Bishkek LLC in 2024, income tax liabilities, if any, in Kyrgyzstan would be borne by the new shareholder of First Fertility Bishkek LLC. There was no assessable income generated from Hong Kong and Cambodia. During the year ended December 31, 2024 excess provision of US$486,706 was reversed as they are no longer deemed to be payable. Net income NewGenIvf’s generated a net income of US$698,032 during the six months period ended June 30, 2025 while there was a net loss of US$387,781 in the six months period ended June 30 ,2024. NewGenIvf’s incurred a